Methoxy polyethylene glycol-epoetin beta

Methoxy polyethylene glycol-epoetin beta (also known as Mircera) is a synthetic, continuous erythropoietin receptor activator used in the treatment of anemia associated with chronic kidney disease (CKD) and chemotherapy-induced anemia. It is a type of erythropoiesis-stimulating agent (ESA) that stimulates the bone marrow to produce more red blood cells.

Mechanism of Action[edit | edit source]

Methoxy polyethylene glycol-epoetin beta works by binding to the erythropoietin receptor on the surface of red blood cell precursors in the bone marrow. This binding activates the receptor and stimulates the production of red blood cells, thereby increasing the overall red blood cell count and improving the symptoms of anemia.

Clinical Use[edit | edit source]

Methoxy polyethylene glycol-epoetin beta is used in the treatment of anemia associated with chronic kidney disease, both in patients on dialysis and those not on dialysis. It is also used to treat anemia caused by chemotherapy in patients with certain types of cancer.

Side Effects[edit | edit source]

Like all medications, methoxy polyethylene glycol-epoetin beta can cause side effects. The most common side effects include headache, diarrhea, and upper respiratory tract infections. Serious side effects can include high blood pressure, blood clots, and severe allergic reactions.

Dosage and Administration[edit | edit source]

Methoxy polyethylene glycol-epoetin beta is administered as an injection under the skin or into a vein. The dosage is determined by the patient's hemoglobin level and overall health status.